Clinical trials: Emphysema or COPD
Alpha 1-Antitrypsin Deficiency, Emphysema
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin…
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
- Trial name
- ASTRAEUS (NCT03636347)
- Testing
- Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Mereo BioPharma
Emphysema or COPD, Emphysema
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
The goal of this clinical trial is to learn if bronchoscopic lung volume reduction with endobronchial thermal liquid ablation (ETLA) works to treat severe emphysema in terms of feasibility and safety.
- Conditions
- Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
- Trial name
- NCT06655428
- Testing
- Endobronchial Therman Liquid Ablation (ETLA)
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Morair Medtech, LLC
Emphysema or COPD
LVRS Versus BLVR in Patients With Homogenous Emphysema, CLUB-HE Trial
This is a prospective randomized clinical trial comparing surgical and bronchoscopic lung volume reduction in patients with advanced homogeneous emphysema suitable for both procedures.
- Trial name
- NCT04781582
- Testing
- Lung volume reduction surgery, Bronchoscopic lung volume reduction
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Universität Duisburg-Essen
Emphysema or COPD
Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema
Patients with severe emphysema have limited options for treatment. Current treatments include lung transplant, lung volume reduction surgery or endobronchial lung volume reduction using valves or coils.
- Trial name
- EFFORT (NCT04520152)
- Testing
- FreeFlowMedical Lung Tensioning Device
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 14 people
- Sponsor
- University Medical Center Groningen
Pulmonary Disease, Chronic Obstructive, Emphysema or COPD
The Microbiome of Sputum, Urine and Feces in Healthy Persons and Chronic Obstructive Pulmonary Disease (COPD) Patients
Extensive studies suggest composition of microbiome of respiratory samples or lung tissues in COPD patients is different from the composition of healthy smokers.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Emphysema or COPD, Microbiota
- Trial name
- COPD (NCT03755505)
- Testing
- obtain samples from sputum, feces and urine
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Chronic Obstructive Pulmonary Disease, Emphysema or COPD
The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility
In some patients with chronic obstructive pulmonary disease (COPD) the breathlessness is caused by hyperinflation of the lungs. This causes difficulty breathing air out and makes it harder to breath in new air and limits the…
- Trial name
- NCT06163131
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Aarhus University Hospital
Coronary Disease, Emphysema or COPD
Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures
The investigators will implement a patient-centered outcomes tool for participants in lung cancer screening programs that receive clinically important incidental findings relevant to heart, breast and lung health.
- Conditions
- Coronary Disease, Emphysema or COPD, Breast Density
- Trial name
- NCT05900544
- Testing
- System implementation of patient-centered incidental findings report
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Montana
Pulmonary Disease, Chronic Obstructive
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- AC4115321 (NCT01372410)
- Testing
- GSK573719, Tiotropium
- Where
- 13 sites in United States
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Emphysema or COPD, Emphysema
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.
- Conditions
- Emphysema or COPD, Emphysema, COPD
- Trial name
- IAB-2 (NCT07119229)
- Testing
- Implantable Artificial Bronchus
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pulmair Medical, Inc.
Emphysema or COPD
Zephyr Etude Post-Inscription (French Registry)
The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support…
- Trial name
- NCT04517916
- Testing
- Zephyr Valve
- Where
- 12 sites in France
- Volunteers
- 155 people
- Sponsor
- Pulmonx Corporation
COPD, Emphysema or COPD
Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD
The aim of this randomized, controlled crossover designed study is to compare the outcomes of receiving autologous, adult stem cells versus placebo among participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Emphysema or COPD, Chronic Bronchitis
- Trial name
- NCT03228121
- Where
- United States
- Sponsor
- Lung Institute
Chronic Pulmonary Obstructive Disease, Emphysema
A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long term safety and efficacy information about the AeriSeal System treatment in patients with advanced emphysema.
- Trial name
- NCT01449175
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Aeris Therapeutics
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension, Chronic Obstructive Lung Disease
Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post BLVR
This study is designed as a prospective study, with the primary endpoint being changes in pulmonary hemodynamic parameters after ELVR in patients with severe emphysema.
- Trial name
- NCT02778802
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Cairo University
Emphysema or Chronic Obstructive Pulmonary Disease
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
Prospective, 2-arm, randomised (2:1), multicentre, open-label clinical trial in patients with severe emphysema. The intervention arm will be treated with Bronchoscopic lung volume reduction in severe emphysema using…
- Trial name
- NCT05717192
- Testing
- InterVapor®-System
- Where
- 12 sites in Germany
- Volunteers
- 224 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Emphysema or COPD
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
The purpose of this protocol is to perform a pilot prospective randomized controlled clinical trial to evaluate the potential role of lung fissure completion strategy (experimental intervention) in addition to endobronchial valve…
- Trial name
- COMPLETE-1 (NCT04801108)
- Testing
- Robotic or VATS lobar fissure completion, Endobronchial valves placement
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Asthma, Allergic Rhinitis
Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
To investigate the Influence of Climatic and Environmental Factors on Respiratory or Allergic Diseases in Sanya.
- Conditions
- Asthma, Allergic Rhinitis, Chronic Obstructive Pulmonary Disease(COPD), Atopic Dermatitis
- Trial name
- NCT05330637
- Testing
- Climate and environment in Sanya
- Where
- China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Asthma, COPD
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
- Trial name
- POLARIS (NCT00667797)
- Testing
- levalbuterol HCl, albuterol Sulfate
- Where
- 18 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat…
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
- Trial name
- ATALANTa (NCT03679598)
- Testing
- Alvelestat (MPH966)
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Alabama at Birmingham